VBIO Archives - BioTuesdays

Developments

Valion announces changes to management and BOD

Valion Bio (NASDAQ: VBIO) has announced that its current chief financial officer, Lisa Wolf, has also been named president and chief operating officer, effective immediately, following the departure of former chief...

September 1, 2026

Developments

Valion announces U.S. government-funded Entolimod studies targeting lethal radiation-induced GI injury

Valion Bio (NASDAQ: VBIO) has announced that the Armed Forces Radiobiology Research Institute (AFRRI), under its contract with the National Institute of Allergy and Infectious Diseases, is conducting a U.S. Department...

August 12, 2026

Developments

Ukraine MoH Accepts Valion Bio’s Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Valion Bio (NASDAQ: VBIO) has announced that the regulatory dossier for its lead candidate, Entolimod for acute radiation syndrome (ARS), has been accepted by Ukraine’s Ministry of Health (MoH) for formal review...

July 22, 2026

Developments

Sheba Medical Center to self-sponsor a trial evaluating Valion Bio’s Entolimod in reducing radiation-induced neutropenia and protecting healthy tissue during cancer radiation therapy

Valion Bio (NASDAQ: VBIO) has announced a major clinical development milestone with the finalization of a clinical trial protocol at Sheba Medical Center, one of the world’s leading hospitals, to evaluate...

July 20, 2026

Developments

Valion advances integrated biodefense, immunology platform

Valion Bio (NASDAQ: VBIO) has provided an update for its Entolimod program—including continued engagement with U.S. government agencies and allied nations on Acute Radiation Syndrome (ARS) preparedness, a demonstrated...

July 14, 2026

Developments

AFRRI/NIAID designs PBI-BM2.5 protocol to evaluate Valion’s Entolimod for GI-ARS

Valion Bio (NASDAQ: VBIO) has announced that the Armed Forces Radiobiology Research Institute (AFRRI), in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), has completed design of the...

June 25, 2026

Developments

Valion confirms HASC initiative to address urgent need for radiation/nuclear countermeasures

Valion Bio (NASDAQ: VBIO) confirmed that the U.S. House Armed Services Committee‘s FY27 National Defense Authorization Act report directs the Assistant Secretary of Defense for Nuclear Deterrence, Chemical, and...

June 11, 2026

Markets

Tivic rebrands as Valion Bio and changes ticker, closes down 28%

After changing its name from Tivic Health Systems (NASDAQ: TIVC) to Valion Bio (NASDAQ: VBIO), effective at market open today, the company’s stock price declined 28% to close at $1.01, after trading as low as $0.865...

April 28, 2026

Tag - VBIO

Valion announces changes to management and BOD

Valion announces U.S. government-funded Entolimod studies targeting lethal radiation-induced GI injury

Ukraine MoH Accepts Valion Bio’s Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

Sheba Medical Center to self-sponsor a trial evaluating Valion Bio’s Entolimod in reducing radiation-induced neutropenia and protecting healthy tissue during cancer radiation therapy

Valion advances integrated biodefense, immunology platform

AFRRI/NIAID designs PBI-BM2.5 protocol to evaluate Valion’s Entolimod for GI-ARS

Valion confirms HASC initiative to address urgent need for radiation/nuclear countermeasures

Tivic rebrands as Valion Bio and changes ticker, closes down 28%

Subscribe